Last updated: March 1, 2026
What is NDC 49884-0250?
NDC 49884-0250 identifies a specific drug product mapped to the National Drug Code system. It corresponds to Bevacizumab (Avastin), typically marketed for oncology and ophthalmology indications.
Market Size and Demand Drivers
Indications and Usage
Bevacizumab is approved for multiple indications, including:
- Colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Ovarian cancer
- Wet age-related macular degeneration (wet AMD)
Market Penetration
The global oncology biologics market was valued at approximately USD 60 billion in 2022, with monoclonal antibodies comprising a significant segment. Bevacizumab accounts for roughly 15% of monoclonal antibody sales in oncology.
Patient Population Estimates
- Approximate annual incidence for colorectal and lung cancers: 2.3 million globally
- Wet AMD affects around 2 million people in the U.S., with anti-VEGF therapies like Bevacizumab accounting for 30% of the ophthalmic anti-VEGF treatments.
Key Competitors
| Product |
Indications |
Market Share (2022) |
Price Range (per vial) |
| Bevacizumab (Avastin) |
Oncology, ophthalmology |
65% |
USD 50–USD 200 |
| Ranibizumab (Lucentis) |
Wet AMD |
25% |
USD 2,000 |
| Aflibercept (Eylea) |
Wet AMD, diabetic retinopathy |
10% |
USD 2,050 |
Price Analysis
Current Pricing Levels
- Oncology indications: USD 50–USD 200 per vial (100 mg)
- Ophthalmic applications: USD 1,950–USD 3,000 for the same dosage form due to formulation differences and process costs
Price Trends
- Biosimilar competition led to a 20% price reduction in U.S. oncology markets since 2021
- Specialty pharmacy distribution can inflate prices by 10-15% relative to wholesale acquisition cost (WAC)
Cost Factors
- Manufacturing costs for monoclonal antibodies hover around USD 100–USD 200 per gram
- R&D and regulatory compliance costs $1–$2 billion over a decade
- Prices reflect patent protections, manufacturing complexity, and market exclusivity
Patent and Regulatory Status
Patent Timeline
- Original patents expired or are set to expire by 2023-2024 in major markets like U.S. and Europe
- Supplemental patents on formulation and delivery extend exclusivity until 2025–2027
Biosimilar Entry
- US FDA approved biosimilars in 2018-2021, reducing prices
- Expected biosimilar launches could cut prices further by 30–50% over the next 2–3 years
Market Outlook and Price Projections
Short-term (Next 1 Year)
- Prices remain stable at current levels; biosimilar competition continues to exert downward pressure
- Market share of biosimilars expected to increase from 10% to 25%, reducing average selling price by 25–30%
Mid-term (Next 3 Years)
- Biosimilars may capture up to 50% of the market segment, with prices dropping 40–50%
- Price per vial in oncology could fall to USD 25–USD 75, depending on market dynamics
Long-term (Next 5 Years)
- Market consolidation and continued biosimilar competition may reduce prices by 50–70% from current levels
- Potential for pricing stabilization at around USD 20–USD 50 per vial in oncology; ophthalmology prices may decline less due to localized demand
Key Market Risks
- Patent litigation delays biosimilar entry
- Regulatory changes impacting approval pathways
- Shift in treatment paradigms favoring oral or targeted therapies
- Patent extensions or new formulations delaying generic competition
Summary
| Parameter |
Current Status |
1-Year Outlook |
3-Year Outlook |
5-Year Outlook |
| Average Price (per vial) |
USD 50–USD 200 |
USD 50–USD 150 |
USD 25–USD 75 |
USD 20–USD 50 |
| Biosimilar Market Penetration |
~10% |
15–25% |
40–50% |
50–70% |
| Market Size (USD) |
USD 3–5 billion (global) |
Stable or declining |
Slight decline due to price reduction |
Continued market erosion |
Key Takeaways
- NDC 49884-0250 corresponds to Bevacizumab, a monoclonal antibody with a significant market share in oncology and ophthalmology.
- Prices are currently driven by brand exclusivity, with substantial reductions expected over the next 3–5 years due to biosimilar competition.
- Biosimilar launches will likely decrease average prices by up to 70%, with the most significant impact on oncology markets.
- The market remains sensitive to patent litigations and regulatory shifts, which can alter projections.
Frequently Asked Questions
-
How does biosimilar competition impact Bevacizumab prices?
Biosimilars typically reduce prices by 30–50%, increasing market penetration and decreasing revenue per vial.
-
What are the key indications influencing market size?
Oncology indications dominate, especially colorectal and lung cancers, accounting for the majority of sales, with ophthalmology contributing a smaller but growing share.
-
Are there regulatory risks affecting future prices?
Yes. Patent disputes and changes in biosimilar approval pathways pose risks to market stability and pricing.
-
How does manufacturing complexity influence pricing?
High manufacturing costs and stringent regulatory compliance maintain elevated prices; biosimilars with simplified processes may eventually lower costs.
-
What are the main factors driving price declines?
Biosimilar entries, market saturation, and patent expirations drive prices downward over 3-5 years.
References
[1] IQVIA. (2022). Global Oncology Market Data. Retrieved from https://www.iqvia.com
[2] FDA. (2021). Biosimilar Product Information. https://www.fda.gov
[3] EvaluatePharma. (2022). Oncology Biologics Market Analysis. Retrieved from https://www.evaluate.com
[4] MarketWatch. (2023). Biosimilar Impact on Oncology Drugs. https://www.marketwatch.com
